<!DOCTYPE html>
<html lang="en-US"><head>
		<meta charset="UTF-8">
		<title>FR940328-2-00053</title>
	</head>
	<body>
		<main>
			<p><!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> April 27, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> <!-- PJG STAG 4703 -->  <!-- PJG ITAG l=69 g=1 f=1 -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=18 g=1 f=1 -->  <USBUREAU>Food and Drug Administration</USBUREAU> <!-- PJG /ITAG -->  <!-- PJG ITAG l=41 g=1 f=1 -->  <RINDOCK>[Docket No. 94N&hyph;0107]</RINDOCK> <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG ITAG l=55 g=1 f=1 --> Chelsea Laboratories, Inc.; Withdrawal of Approval of 26 Abbreviated New Drug Applications <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <AGENCY> <!-- PJG ITAG l=10 g=1 f=2 --> AGENCY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Food and Drug Administration, HHS. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </AGENCY> <ACTION> <!-- PJG ITAG l=10 g=1 f=2 --> ACTION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Notice. <!-- PJG /ITAG -->  <!-- PJG ITAG l=59 g=1 f=1 -->  <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </ACTION> <SUMMARY> <!-- PJG ITAG l=10 g=1 f=2 --> SUMMARY:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> The Food and Drug Administration (FDA) is withdrawing approval of 26 abbreviated new drug applications (ANDA's) held by Chelsea Laboratories, Inc., 896 Orlando Ave., West Hempstead, NY 11552 (Chelsea). Chelsea notified the agency in writing that the drug products were no longer marketed and requested that the approval of the applications be withdrawn. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUMMARY> <DATE> <!-- PJG ITAG l=10 g=1 f=2 --> EFFECTIVE DATE:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> April 27, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </DATE> <FURTHER> <!-- PJG ITAG l=10 g=1 f=2 --> FOR FURTHER INFORMATION CONTACT:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Lola E. Batson, Center for Drug Evaluation and Research (HFD&hyph;360), Food and Drug Administration, 7500 Standish Pl., Rockville, MD 20855, 301&hyph;594&hyph;1038. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FURTHER> <SUPPLEM> <!-- PJG ITAG l=10 g=1 f=2 --> SUPPLEMENTARY INFORMATION:  <!-- PJG /ITAG -->  <!-- PJG ITAG l=10 g=1 f=1 --> Chelsea informed FDA that the drugs listed in the table in this document are no longer marketed and requested that FDA withdraw approval of the applications. Chelsea has also, by its request, waived its opportunity for a hearing. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <TABLE>  <!-- PJG tableformat 2,L2,nj,i1,s25,r80  -->  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1ANDA no.  <!-- PJG 0012 frnewline -->  <!-- PJG 007 0150 intable --> 1Drug <!-- PJG 0012 frnewline -->  <!-- PJG 007 0152 intable -->   <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> 70&hyph;000 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Sulfamethoxazole and Trimethoprim Tablets, U.S.P, 800 milligrams (mg)/160 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 70&hyph;002 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Sulfamethoxazole and Trimethoprim Tablets, U.S.P, 400 mg/80 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 71&hyph;603 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Clofibrate Capsules, U.S.P., 500 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 71&hyph;635 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Indomethacin Capsules, 50 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 85&hyph;167 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Procainamide Hydrochloride Capsules, U.S.P., 250 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 85&hyph;815 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Amitriptyline Hydrochloride Tablets, 50 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 85&hyph;816 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Amitriptyline Hydrochloride Tablets, 10 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 85&hyph;817 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Amitriptyline Hydrochloride Tablets, 25 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 85&hyph;819 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Amitriptyline Hydrochloride Tablets, 75 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 85&hyph;820 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Amitriptyline Hydrochloride Tablets, 100 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 86&hyph;150 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Probenecid Tablets, 500 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 86&hyph;151 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Phenylbutazone Tablets, U.S.P., 100 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 86&hyph;161 <!-- PJG 007 0104 intable --> Methylprednisolone Tablets, 4 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 86&hyph;237 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Butalbital, Aspirin, and Caffeine Tablets, U.S.P., 50 mg/325 mg/40 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 86&hyph;705 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Hydroxyzine Pamoate Capsules, U.S.P., 50 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 86&hyph;827 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Hydroxyzine Hydrochloride Tablets, U.S.P., 10 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 86&hyph;829 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Hydroxyzine Hydrochloride Tablets, U.S.P., 25 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 86&hyph;836 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Hydroxyzine Hydrochloride Tablets, U.S.P., 50 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 86&hyph;840 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Hydroxyzine Pamoate Capsules, U.S.P., 25 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 86&hyph;865 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Chlorpropamide Tablets, 100 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 87&hyph;020 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Procainamide Hydrochloride Capsules, U.S.P., 375 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 87&hyph;021 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Procainamide Hydrochloride Capsules, U.S.P., 500 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 87&hyph;078 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Spironolactone Tablets, 25 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 87&hyph;082 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Chlorthalidone Tablets, 50 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 87&hyph;756 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Phenylbutazone Capsules, U.S.P., 100 mg <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline --> 87&hyph;785 <!-- PJG 0012 frnewline -->  <!-- PJG 007 0104 intable --> Quinidine Gluconate Sustained Release Tablets, U.S.P., 324 mg <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  </TABLE>   <!-- PJG 0012 frnewline -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=11 g=1 f=1 --> Therefore, under section 505(e) of the Federal Food, Drug, and Cosmetic Act (21 U.S.C. 355(e)) and under authority delegated to the Director, Center for Drug Evaluation and Research (21 CFR 5.82), approval of the ANDA's listed above, and all amendments and supplements thereto, is hereby withdrawn, effective  April 27, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG -->  <!-- PJG QTAG 04 --> <!-- PJG /QTAG -->  <!-- PJG 0012 frnewline -->  <!-- PJG ITAG l=21 g=1 f=1 --> Dated: March 14, 1994. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SUPPLEM> <SIGNER> <!-- PJG ITAG l=06 g=1 f=1 --> Roger Williams, <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNER> <SIGNJOB> <!-- PJG ITAG l=04 g=1 f=1 --> Acting Director, Center for Drug Evaluation and Research. <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </SIGNJOB> <FRFILING> <!-- PJG ITAG l=40 g=1 f=1 --> [FR Doc. 94&hyph;7203 Filed 3&hyph;25&hyph;94; 8:45 am] <!-- PJG 0012 frnewline -->  <!-- PJG /ITAG --> </FRFILING> <BILLING> <!-- PJG ITAG l=68 g=1 f=1 --> BILLING CODE 4160&hyph;01&hyph;F <!-- PJG /ITAG --> </BILLING>  <!-- PJG /STAG --></p>
		</main>
</body></html>
            